

## CACI – Psoriasis Worksheet

(Updated 11/27/2024)

To determine the applicant's eligibility for certification, the AME must review a current, detailed Clinical Progress Note generated from a clinic visit with the treating physician or specialist **no more than 90 days prior** to the AME exam. If the applicant **meets ALL the acceptable certification criteria** listed below, the AME can issue. Applicants for first- or second- class must provide this information annually; applicants for third-class must provide the information with each required exam.

AME MUST REVIEW	ACCEPTABLE CERTIFICATION CRITERIA
A current, detailed Clinical Progress Note from the treating physician	<p><input type="checkbox"/> Condition is stable with NO systemic symptoms and NO limitation to strength, function, or range of motion which would interfere with flight duties.</p> <p><input type="checkbox"/> Severity is mild to moderate.</p> <p>NOTE: If co-morbid conditions are present, see corresponding page. If psoriatic arthritis, see arthritis page.</p>
Causes	<p><input type="checkbox"/> Most subtypes to include: guttate psoriasis, plaque psoriasis.</p> <p><b>Not acceptable:</b> pustular psoriasis, erythrodermic psoriasis.</p>
Lab	<p><input type="checkbox"/> If on methotrexate: Normal CBC, Liver Function Test, and Creatinine within the past 90 days.</p> <p>OR</p> <p><input type="checkbox"/> Not taking methotrexate</p>
Medications for condition  Combinations acceptable for CACI Include: <ul style="list-style-type: none"><li>• Topical medication +</li><li>• Methotrexate +</li><li>• Any single agent listed</li></ul> <b>KEY:</b> Interleukin Inhibitors (IL) Phosphodiesterase-4 Enzyme Inhibitor (PDE4) Tumor necrosis factor inhibitors (TNF)  *Biologics do not have generic; they have biosimilar.	<p><input type="checkbox"/> Topical medication(s) and/or</p> <p><input type="checkbox"/> methotrexate (Trexall) and/or</p> <p><input type="checkbox"/> Any single medication listed below after a 2-week ground trial and:</p> <ul style="list-style-type: none"><li>• <b>No post-dose observation time:</b><ul style="list-style-type: none"><li>▪ apremilast (Otezla) - PD4E</li></ul></li><li>• <b>4-hour post-dose observation time:</b><ul style="list-style-type: none"><li>▪ adalimumab (Humira or FDA approved biosimilar*) - TNF</li><li>▪ certolizumab (Cimzia) - TNF</li><li>▪ etanercept (Enbrel) - TNF</li><li>▪ guselkumab (Tremfya) - IL</li><li>▪ ixekizumab (Taltz) - IL</li><li>▪ risankizumab (Skyrizi) - IL</li><li>▪ secukinumab (Cosentyx) – IL</li><li>▪ tildrakizumab (Ilumya) - IL</li><li>▪ ustekinumab (Stelara) - IL</li></ul></li><li>• <b>24-hour post-dose observation time:</b><ul style="list-style-type: none"><li>▪ infliximab (Inflect; Remicade; Renflexis) - TNF</li></ul></li></ul>

### AME MUST NOTE in Block 60 one of the following:

CACI qualified Psoriasis. (Documents do not need to be submitted to the FAA.)

Has current OR previous SI/AASI but now CACI qualified Psoriasis.

NOT CACI qualified Psoriasis. I have deferred. (Submit supporting documents.)